NASH Clinical Trial
Official title:
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection for Subcutaneous Use in Healthy Subjects
This will be a phase I, randomized, double-blind, placebo-controlled, single-dose escalation study. This study will be conducted in three periods: the screening period , the treatment period and the follow-up period. This study aims to evaluate the pharmacokinetics, target engagement and pharmacodynamic biomarkers of ASC47 in healthy subjects.
The study will consist of five cohorts, each with different doses of ASC47. Cohorts 1 and 2 have 6 subjects, of which 4 subjects will receive the single dose of ASC47 and 2 subjects will receive matching placebo. Cohorts 3, 4 and 5 have 8 subjects, of which 6 subjects will receive the single dose of ASC47 and 2 subjects will receive matching placebo. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
Completed |
NCT02923154 -
Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
|
Phase 2 | |
Withdrawn |
NCT03980912 -
Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
|
||
Terminated |
NCT04565717 -
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 1 | |
Recruiting |
NCT04302051 -
Assessment of Fatty Liver With Thermo-acoustic Device
|
||
Recruiting |
NCT05327127 -
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
|
Phase 2 | |
Completed |
NCT06348706 -
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
|
Phase 3 | |
Recruiting |
NCT05935488 -
Early Liver Disease Breath Detection
|
||
Active, not recruiting |
NCT06315361 -
DIAbetes and NAFLD
|
||
Completed |
NCT03187496 -
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
|
Phase 1 | |
Recruiting |
NCT04442334 -
The European NAFLD Registry
|
||
Recruiting |
NCT06338969 -
The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis
|
N/A | |
Completed |
NCT05193916 -
A Phase II Clinical Trial of Chiglitazar for NASH
|
Phase 2 | |
Active, not recruiting |
NCT05669677 -
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
|
||
Not yet recruiting |
NCT04783116 -
Plant Stanols and Liver Inflammation in Overweight and Obese Children
|
N/A | |
Recruiting |
NCT06193629 -
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
|
N/A | |
Completed |
NCT04006145 -
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
|
Phase 2 | |
Recruiting |
NCT04232293 -
Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT06410924 -
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
|
Phase 2 |